SCHEMBL25445

SCHEMBL25445

CN(C)c1c([N+](=O)[O-])cc(N2C(=O)C=CC2=O)cc1[N+](=O)[O-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 4/20 1.00
MAPT P10636 7/20 0.49
ALDH1A1 P00352 4/20 0.49
HSP90AA1 P07900 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
HPGD P15428 2/20 0.49
PKM P14618 2/20 0.49
HTT P42858 2/20 0.49
NLRP1 Q9C000 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HPN P05981 1/20 0.45
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
MGLL Q99685 4/20 0.36
FAAH O00519 2/20 0.36
LMNA P02545 2/20 0.36
NSD2 O96028 1/20 0.36
G6PD P11413 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108657 0.84 CCR6 (0.71) CCR6MAPTALDH1A1HSP90AA1NPSR1
SCHEMBL5577178 0.80 CCR6 (0.66) CCR6MAPTALDH1A1HSP90AA1NPSR1
SCHEMBL4954431 0.78 CCR6 (0.63) CCR6MAPTALDH1A1HSP90AA1NPSR1
SCHEMBL28192920 0.76 CCR6 (0.61) CCR6MAPTALDH1A1HSP90AA1NPSR1
SCHEMBL28262952 0.75 CCR6 (0.59) CCR6MAPTALDH1A1NPSR1HPGD
SCHEMBL10664728 0.74 CCR6 (0.64) CCR6MAPTALDH1A1HSP90AA1NPSR1
SCHEMBL29510540 0.73 CCR6 (0.68) CCR6MAPTALDH1A1HSP90AA1NPSR1
SCHEMBL11646163 0.73 CCR6 (0.68) CCR6MAPTALDH1A1HSP90AA1NPSR1
SCHEMBL20240381 0.72 KMT2A (0.67) CCR6MAPTALDH1A1NPSR1HPGD
SCHEMBL11514139 0.72 GPR35 (0.57) CCR6MAPTALDH1A1NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276107-A1 HYDROGEL SYSTEMS AND METHODS FOR TREATING FISTULA AND OTHER INDICATIONS TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION (US) 2025-09-04 US claimed
US-8513350-B2 Forming patterned film; radiation transparent, reduced dielectrics, solvent resistance, waterproofing, acid and alkali resistance, heat resistance, adhesives properties to substrate JNC CORPORATION (JP) 2013-08-20 US claimed
US-20090191386-A1 POSITIVE PHOTOSENSITIVE POLYMER COMPOSITION CHISSO CORPORATION (JP) 2009-07-30 US claimed
US-20080207807-A1 POSITIVE TYPE PHOTOSENSITIVE RESIN COMPOSITION CHISSO CORPORATION (JP) 2008-08-28 US claimed
EP-0527186-A4 UNIV ILLINOIS (US) 1995-01-18 EP claimed
EP-0527186-A1 PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS The Board of Trustees for the University of Illinois (US) 1993-02-17 EP claimed
WO-1991016820-A1 PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1991-11-14 WO claimed
US-4318981-A Homogeneous specific binding assay employing an intramolecularly modulated photogenic enzyme substrate label MILES LABORATORIES, INC. (US) 1982-03-09 US claimed
EP-4061961-B1 METHOD FOR DOUBLE STRAND SEQUENCING OXFORD NANOPORE TECH PLC (GB) 2026-04-08 EP disclosed
US-20260072009-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-12 US disclosed
US-20260072008-A1 METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE UNIV OXFORD INNOVATION LTD (GB) 2026-03-12 US disclosed
US-20260063618-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE Oxford Nanopore Technolgies PLC (GB) 2026-03-05 US disclosed
EP-4689159-A1 METHOD AND KITS Oxford Nanopore Technologies PLC (GB) 2026-02-11 EP disclosed
EP-4270008-B1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE OXFORD NANOPORE TECH PLC (GB) 2026-02-04 EP disclosed
WO-2000012536-A2 LIPID MATRIX-ASSISTED CHEMICAL LIGATION AND SYNTHESIS OF MEMBRANE POLYPEPTIDES GRYPHON SCIENCES (US) 2000-03-09 WO disclosed
WO-1999011655-A1 MODULAR PROTEIN LIBRARIES AND METHODS OF PREPARATION GRYPHON SCIENCES (US) 1999-03-11 WO disclosed
EP-0721505-A1 PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE INNOGENETICS N.V. (BE) 1996-07-17 EP disclosed
WO-1996004385-A2 PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE INNOGENETICS N.V. (BE) 1996-02-15 WO disclosed
US-5242892-A With 5-aminolevulinic acid THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1993-09-07 US disclosed
US-4111879-A RESIN AND AN N-ARYL-MALEIMIDE IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260072008-A1 METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE MAX, NPPA, NUP210 CCR6 1584/4885MAPT 2775/4885ALDH1A1 4882/4885
US-20260063618-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE NUP210, NPPA, NUP160 CCR6 1754/4885MAPT 2543/4885ALDH1A1 4884/4885
US-20260072009-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE NUP210, SLC9A2, SLC9A3 CCR6 3030/4885MAPT 2784/4885ALDH1A1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.